Germline variants in tumor suppressor FBXW7 lead to impaired ubiquitination and a neurodevelopmental syndrome

dc.contributor.authorTUDP Study Group
dc.contributor.authorBroad Center for Mendelian Genomics
dc.contributor.departmentFaculty of Medicine
dc.date.accessioned2025-11-20T08:47:08Z
dc.date.available2025-11-20T08:47:08Z
dc.date.issued2022-04-01
dc.descriptionFunding Information: I.E.S. has served on scientific advisory boards for UCB, Eisai, GlaxoSmithKline, BioMarin, Nutricia, Rogcon, Chiesi, Encoded Therapeutics, Xenon Pharmaceuticals, and Knopp Biosciences; has received speaker honoraria from GlaxoSmithKline, UCB, BioMarin, Biocodex, and Eisai; has received funding for travel from UCB, Biocodex, GlaxoSmithKline, Biomarin and Eisai; has served as an investigator for Zogenix, Zynerba, Ultragenyx, GW Pharma, UCB, Eisai, Anavex Life Sciences, Ovid Therapeutics, Epygenyx, Encoded Therapeutics and Marinus; and has consulted for Zynerba Pharmaceuticals, Atheneum Partners, Ovid Therapeutics, Care Beyond Diagnosis, Epilepsy Consortium and UCB. She may accrue future revenue on pending patent WO2009/086591; her patent for SCN1A testing is held by Bionomics and is licensed to various diagnostic companies; and she has a patent for a molecular diagnostic/therapeutic target for benign familial infantile epilepsy (BFIE) (PRRT2), WO/2013/059884. She receives and/or has received research support from the National Health and Medical Research Council of Australia, Medical Research Future Fund, Health Research Council of New Zealand, CURE, Australian Epilepsy Research Fund, and the National Institute of Neurological Disorders and Stroke of the National Institutes of Health. J.P. is co-chief scientific officer for Global Gene Corp. All other authors declare no competing interests. Funding Information: The authors thank the affected individuals and all family members for participating in this research. Please see the supplemental information for a complete list of Acknowledgments and funding. I.E.S. has served on scientific advisory boards for UCB, Eisai, GlaxoSmithKline, BioMarin, Nutricia, Rogcon, Chiesi, Encoded Therapeutics, Xenon Pharmaceuticals, and Knopp Biosciences; has received speaker honoraria from GlaxoSmithKline, UCB, BioMarin, Biocodex, and Eisai; has received funding for travel from UCB, Biocodex, GlaxoSmithKline, Biomarin and Eisai; has served as an investigator for Zogenix, Zynerba, Ultragenyx, GW Pharma, UCB, Eisai, Anavex Life Sciences, Ovid Therapeutics, Epygenyx, Encoded Therapeutics and Marinus; and has consulted for Zynerba Pharmaceuticals, Atheneum Partners, Ovid Therapeutics, Care Beyond Diagnosis, Epilepsy Consortium and UCB. She may accrue future revenue on pending patent WO2009/086591; her patent for SCN1A testing is held by Bionomics and is licensed to various diagnostic companies; and she has a patent for a molecular diagnostic/therapeutic target for benign familial infantile epilepsy (BFIE) (PRRT2), WO/2013/059884. She receives and/or has received research support from the National Health and Medical Research Council of Australia, Medical Research Future Fund, Health Research Council of New Zealand, CURE, Australian Epilepsy Research Fund, and the National Institute of Neurological Disorders and Stroke of the National Institutes of Health. J.P. is co-chief scientific officer for Global Gene Corp. All other authors declare no competing interests. Publisher Copyright: © 2022 American Society of Human Genetics Copyright © 2022 American Society of Human Genetics. Published by Elsevier Inc. All rights reserved.en
dc.description.abstractNeurodevelopmental disorders are highly heterogenous conditions resulting from abnormalities of brain architecture and/or function. FBXW7 (F-box and WD-repeat-domain-containing 7), a recognized developmental regulator and tumor suppressor, has been shown to regulate cell-cycle progression and cell growth and survival by targeting substrates including CYCLIN E1/2 and NOTCH for degradation via the ubiquitin proteasome system. We used a genotype-first approach and global data-sharing platforms to identify 35 individuals harboring de novo and inherited FBXW7 germline monoallelic chromosomal deletions and nonsense, frameshift, splice-site, and missense variants associated with a neurodevelopmental syndrome. The FBXW7 neurodevelopmental syndrome is distinguished by global developmental delay, borderline to severe intellectual disability, hypotonia, and gastrointestinal issues. Brain imaging detailed variable underlying structural abnormalities affecting the cerebellum, corpus collosum, and white matter. A crystal-structure model of FBXW7 predicted that missense variants were clustered at the substrate-binding surface of the WD40 domain and that these might reduce FBXW7 substrate binding affinity. Expression of recombinant FBXW7 missense variants in cultured cells demonstrated impaired CYCLIN E1 and CYCLIN E2 turnover. Pan-neuronal knockdown of the Drosophila ortholog, archipelago, impaired learning and neuronal function. Collectively, the data presented herein provide compelling evidence of an F-Box protein-related, phenotypically variable neurodevelopmental disorder associated with monoallelic variants in FBXW7.en
dc.description.versionPeer revieweden
dc.format.extent17
dc.format.extent2172218
dc.format.extent601-617
dc.identifier.citationTUDP Study Group & Broad Center for Mendelian Genomics 2022, 'Germline variants in tumor suppressor FBXW7 lead to impaired ubiquitination and a neurodevelopmental syndrome', American Journal of Human Genetics, vol. 109, no. 4, pp. 601-617. https://doi.org/10.1016/j.ajhg.2022.03.002en
dc.identifier.doi10.1016/j.ajhg.2022.03.002
dc.identifier.issn0002-9297
dc.identifier.other56720428
dc.identifier.otherde8a2159-1661-44de-bd54-a0566a5aaa4f
dc.identifier.other85127470624
dc.identifier.other35395208
dc.identifier.otherunpaywall: 10.1016/j.ajhg.2022.03.002
dc.identifier.urihttps://hdl.handle.net/20.500.11815/6738
dc.language.isoen
dc.relation.ispartofseriesAmerican Journal of Human Genetics; 109(4)en
dc.relation.urlhttps://www.scopus.com/pages/publications/85127470624en
dc.rightsinfo:eu-repo/semantics/openAccessen
dc.subjectbrain malformationen
dc.subjectepilepsyen
dc.subjectF-box proteinen
dc.subjectFBXW7en
dc.subjectgastrointestinal issuesen
dc.subjectglobal developmental delayen
dc.subjecthypotoniaen
dc.subjectintellectual disabilityen
dc.subjectmacrocephalyen
dc.subjectNeurodevelopmenten
dc.subjectProteasome Endopeptidase Complex/metabolismen
dc.subjectHumansen
dc.subjectGerm Cellsen
dc.subjectUbiquitinationen
dc.subjectGerm-Line Mutationen
dc.subjectF-Box-WD Repeat-Containing Protein 7/chemistryen
dc.subjectUbiquitin-Protein Ligases/geneticsen
dc.subjectNeurodevelopmental Disorders/geneticsen
dc.subjectGenetics (clinical)en
dc.subjectGeneticsen
dc.titleGermline variants in tumor suppressor FBXW7 lead to impaired ubiquitination and a neurodevelopmental syndromeen
dc.type/dk/atira/pure/researchoutput/researchoutputtypes/contributiontojournal/articleen

Skrár

Original bundle

Niðurstöður 1 - 1 af 1
Nafn:
1_s2.0_S0002929722000982_main.pdf
Stærð:
2.07 MB
Snið:
Adobe Portable Document Format

Undirflokkur